CSNK1G1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL234334	1.00	5/20
SCHEMBL232042	1.00	4/20
SCHEMBL90887	0.49	4/20
SCHEMBL90935	0.49	4/20
Bi-2536 (SCHEMBL372489)	1.00	3/20
SCHEMBL376821	0.90	3/20
SCHEMBL376236	0.88	3/20
SCHEMBL376134	0.85	3/20
SCHEMBL375839	0.85	3/20
SCHEMBL376417	0.84	3/20
SCHEMBL375825	0.83	3/20
SCHEMBL376040	0.83	3/20
SCHEMBL376263	0.82	3/20
SCHEMBL376100	0.81	3/20
SCHEMBL376093	0.81	3/20
SCHEMBL376152	0.81	3/20
SCHEMBL376368	0.81	3/20
SCHEMBL376142	0.79	3/20
SCHEMBL376312	0.79	3/20
SCHEMBL376288	0.78	3/20

Clinical trials — most relevant to CSNK1G1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex	nan	COMPLETED
Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease	nan	COMPLETED
Genetic Markers of CHD Risk in Men and Women	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED
Family Blood Pressure Program - HyperGEN	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Genetic Analysis of Gray Platelet Syndrome	nan	COMPLETED
Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease	nan	COMPLETED
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Genetics and Psychopathology in the 22q11 Deletion Syndrome	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CSNK1G1 binder may also engage these)

Protein	Name	Similarity
Q8BTH8	—	1.000	Q8BTH8 →
Q8BVP5	—	1.000	Q8BVP5 →
Q5PRD4	—	1.000	Q5PRD4 →
Q62762	—	1.000	Q62762 →
Q5ZJS0	—	1.000	Q5ZJS0 →
CSNK1G2	Casein kinase I isoform gamma-2	1.000	landscape →
A7E3X2	—	0.999	A7E3X2 →
Q5R4V3	—	0.998	Q5R4V3 →
Q8C4X2	—	0.998	Q8C4X2 →
Q6NRT0	—	0.998	Q6NRT0 →
Q62761	—	0.998	Q62761 →
Q4R9A9	—	0.997	Q4R9A9 →
CSNK1G3	Casein kinase I isoform gamma-3	0.996	landscape →
Q62763	—	0.995	Q62763 →
Q39050	—	0.995	Q39050 →
P40236	—	0.991	P40236 →
Q93Z18	—	0.991	Q93Z18 →
P40233	—	0.990	P40233 →
Q8WQ99	—	0.989	Q8WQ99 →
Q9ZUP4	—	0.989	Q9ZUP4 →
Q6P647	—	0.989	Q6P647 →
P40234	—	0.988	P40234 →
A0A0J9UVX2	—	0.988	A0A0J9UVX2 →
CSNK1E	Casein kinase I isoform epsilon	0.988	landscape →
G4MYB0	—	0.987	G4MYB0 →
Q5RC72	—	0.987	Q5RC72 →
Q6P3K7	—	0.987	Q6P3K7 →
O74135	—	0.987	O74135 →
Q6K9N1	—	0.987	Q6K9N1 →
Q5ZLL1	—	0.986	Q5ZLL1 →